US courts need to revisit the patentability of diagnostic tests under section 101, according to Memorial Sloan Kettering Cancer Center’s chief IP counsel.
A US health insurance provider is suing a subsidiary of Johnson & Johnson for filing “sham” patent litigation in a bid to stop generic forms of a prostate cancer treatment from entering the market.
The European Parliament has voted to approve the supplementary protection certificate manufacturing waiver, which will allow the stockpiling of generic versions of patented drugs.
Plans by Canada’s government to improve access to generic drugs could deter pharmaceutical companies from releasing brand medicine in the country, according to an internal government report.
The US Supreme Court has declined to hear a closely-watched case on tribal immunity involving pharmaceutical company Allergan and the Saint Regis Mohawk Tribe, a Native American tribe.
Amgen subsidiary Immunex has appealed against a Patent Trial and Appeal Board decision which invalidated a patent claiming antibodies that target human interleukin-4 receptors.
Pharmaceutical company Impax Laboratories engaged in illegal pay-for-delay settlements to stop a generic version of one of its medications from entering the market, the US Federal Trade Commission has ruled.
The US Court of Appeals for the Federal Circuit yesterday, March 28, overturned a district court decision and handed a victory to pharmaceutical companies Endo and Mallinckrodt.
The UK Supreme Court’s decision in Actavis v Eli Lilly confirms that a multi-factorial judgement should be used to determine whether an invention is obvious or not, lawyers have told WIPR.
The UK Supreme Court has ruled in favour of Actavis (which has been acquired by Teva) and Mylan in a patent dispute against Eli Lilly, after an earlier court found that one of Eli Lilly’s patents was invalid for lacking an inventive step.